T follicular helper cells and antibody response to Hepatitis B virus vaccine in HIV-1 infected children receiving ART

Abstract HBV vaccine has 95% efficacy in children to prevent HBV infection and related cancer. We conducted a prospective study in HIV-1 infected children receiving ART (n = 49) and controls (n = 63) to assess humoral and cellular responses to HBV vaccine provided with three doses under an accelerat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yonas Bekele, Desalegn Yibeltal, Kidist Bobosha, Temesgen E. Andargie, Mahlet Lemma, Meseret Gebre, Eyasu Mekonnen, Abiy Habtewold, Anna Nilsson, Abraham Aseffa, Rawleigh Howe, Francesca Chiodi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/272dfd8f75b141c7a52e87bc3c35d710
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:272dfd8f75b141c7a52e87bc3c35d710
record_format	dspace
spelling	oai:doaj.org-article:272dfd8f75b141c7a52e87bc3c35d7102021-12-02T16:06:28ZT follicular helper cells and antibody response to Hepatitis B virus vaccine in HIV-1 infected children receiving ART10.1038/s41598-017-09165-62045-2322https://doaj.org/article/272dfd8f75b141c7a52e87bc3c35d7102017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-09165-6https://doaj.org/toc/2045-2322Abstract HBV vaccine has 95% efficacy in children to prevent HBV infection and related cancer. We conducted a prospective study in HIV-1 infected children receiving ART (n = 49) and controls (n = 63) to assess humoral and cellular responses to HBV vaccine provided with three doses under an accelerated schedule of 4 weeks apart. At 1 month post-vaccination all children, except 4 HIV-1 infected, displayed protective antibody (ab) titers to HBV vaccine; ab titers were lower in infected children (P < 0.0001). Ab titers decreased (P < 0.0001) in both HIV-1 infected and control children at 6 months. The frequency of circulating Tfh (cTFh) cells was 20.3% for controls and 20.8% for infected children prior to vaccination and remained comparable post-vaccination. Cytokine expression by cTfh cells upon activation with HBV antigen was comparable in the two groups at baseline and 1 month post-vaccination. Higher plasma levels (P < 0.0001) of CXCL13 were found in infected children which correlated with cTfh cell frequency at baseline. In conclusion, a lower ab response to HBV vaccine was measured in HIV-1 infected children. The frequency and activation profile of cTfh cells was comparable in infected children and controls suggesting that cells other than Tfh cells are responsible for impaired ab response to HBV vaccine.Yonas BekeleDesalegn YibeltalKidist BoboshaTemesgen E. AndargieMahlet LemmaMeseret GebreEyasu MekonnenAbiy HabtewoldAnna NilssonAbraham AseffaRawleigh HoweFrancesca ChiodiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yonas Bekele Desalegn Yibeltal Kidist Bobosha Temesgen E. Andargie Mahlet Lemma Meseret Gebre Eyasu Mekonnen Abiy Habtewold Anna Nilsson Abraham Aseffa Rawleigh Howe Francesca Chiodi T follicular helper cells and antibody response to Hepatitis B virus vaccine in HIV-1 infected children receiving ART
description	Abstract HBV vaccine has 95% efficacy in children to prevent HBV infection and related cancer. We conducted a prospective study in HIV-1 infected children receiving ART (n = 49) and controls (n = 63) to assess humoral and cellular responses to HBV vaccine provided with three doses under an accelerated schedule of 4 weeks apart. At 1 month post-vaccination all children, except 4 HIV-1 infected, displayed protective antibody (ab) titers to HBV vaccine; ab titers were lower in infected children (P < 0.0001). Ab titers decreased (P < 0.0001) in both HIV-1 infected and control children at 6 months. The frequency of circulating Tfh (cTFh) cells was 20.3% for controls and 20.8% for infected children prior to vaccination and remained comparable post-vaccination. Cytokine expression by cTfh cells upon activation with HBV antigen was comparable in the two groups at baseline and 1 month post-vaccination. Higher plasma levels (P < 0.0001) of CXCL13 were found in infected children which correlated with cTfh cell frequency at baseline. In conclusion, a lower ab response to HBV vaccine was measured in HIV-1 infected children. The frequency and activation profile of cTfh cells was comparable in infected children and controls suggesting that cells other than Tfh cells are responsible for impaired ab response to HBV vaccine.
format	article
author	Yonas Bekele Desalegn Yibeltal Kidist Bobosha Temesgen E. Andargie Mahlet Lemma Meseret Gebre Eyasu Mekonnen Abiy Habtewold Anna Nilsson Abraham Aseffa Rawleigh Howe Francesca Chiodi
author_facet	Yonas Bekele Desalegn Yibeltal Kidist Bobosha Temesgen E. Andargie Mahlet Lemma Meseret Gebre Eyasu Mekonnen Abiy Habtewold Anna Nilsson Abraham Aseffa Rawleigh Howe Francesca Chiodi
author_sort	Yonas Bekele
title	T follicular helper cells and antibody response to Hepatitis B virus vaccine in HIV-1 infected children receiving ART
title_short	T follicular helper cells and antibody response to Hepatitis B virus vaccine in HIV-1 infected children receiving ART
title_full	T follicular helper cells and antibody response to Hepatitis B virus vaccine in HIV-1 infected children receiving ART
title_fullStr	T follicular helper cells and antibody response to Hepatitis B virus vaccine in HIV-1 infected children receiving ART
title_full_unstemmed	T follicular helper cells and antibody response to Hepatitis B virus vaccine in HIV-1 infected children receiving ART
title_sort	t follicular helper cells and antibody response to hepatitis b virus vaccine in hiv-1 infected children receiving art
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/272dfd8f75b141c7a52e87bc3c35d710
work_keys_str_mv	AT yonasbekele tfollicularhelpercellsandantibodyresponsetohepatitisbvirusvaccineinhiv1infectedchildrenreceivingart AT desalegnyibeltal tfollicularhelpercellsandantibodyresponsetohepatitisbvirusvaccineinhiv1infectedchildrenreceivingart AT kidistbobosha tfollicularhelpercellsandantibodyresponsetohepatitisbvirusvaccineinhiv1infectedchildrenreceivingart AT temesgeneandargie tfollicularhelpercellsandantibodyresponsetohepatitisbvirusvaccineinhiv1infectedchildrenreceivingart AT mahletlemma tfollicularhelpercellsandantibodyresponsetohepatitisbvirusvaccineinhiv1infectedchildrenreceivingart AT meseretgebre tfollicularhelpercellsandantibodyresponsetohepatitisbvirusvaccineinhiv1infectedchildrenreceivingart AT eyasumekonnen tfollicularhelpercellsandantibodyresponsetohepatitisbvirusvaccineinhiv1infectedchildrenreceivingart AT abiyhabtewold tfollicularhelpercellsandantibodyresponsetohepatitisbvirusvaccineinhiv1infectedchildrenreceivingart AT annanilsson tfollicularhelpercellsandantibodyresponsetohepatitisbvirusvaccineinhiv1infectedchildrenreceivingart AT abrahamaseffa tfollicularhelpercellsandantibodyresponsetohepatitisbvirusvaccineinhiv1infectedchildrenreceivingart AT rawleighhowe tfollicularhelpercellsandantibodyresponsetohepatitisbvirusvaccineinhiv1infectedchildrenreceivingart AT francescachiodi tfollicularhelpercellsandantibodyresponsetohepatitisbvirusvaccineinhiv1infectedchildrenreceivingart
_version_	1718384951290757120

T follicular helper cells and antibody response to Hepatitis B virus vaccine in HIV-1 infected children receiving ART

Ejemplares similares